NCT01785329View on ClinicalTrials.gov

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Hypercholesterolemia
Interventions
DRUG

alirocumab SAR236553 (REGN727)

Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Trial Locations (1)

NW10 7EW

Investigational Site Number 826001, London

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01785329 - Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects | Biotech Hunter | Biotech Hunter